
    
      This is a phase IV, randomized, open label, 2-arm trial. It will be performed in six malaria
      sentinel site around the Democratic Republic of the Congo. Children aged 6 to 59 months with
      confirmed Plasmodium falciparum uncomplicated malaria will be enrolled after informed consent
      granted by a parent or guardian. They will be randomized to receive either
      artesunate-amodiaquine or artemether lumefrantrine during 3 days (directly observed
      treatment) and then followed up until day 28. At each visit, clinical examination will be
      done and malaria testing as well. Hemoglobin level will be measured on recruitment day and
      then every two weeks until day 28.
    
  